Enalapril
- Generic Name
- Enalapril
- Brand Names
- Epaned, Vaseretic, Vasotec, Aqumeldi
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 75847-73-3
- Unique Ingredient Identifier
- 69PN84IO1A
- Background
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...
- Indication
Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction
- Associated Therapies
- -
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 621
- Registration Number
- NCT02900378
- Locations
- 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom
Expression and Function of the Renin-Angiotensin System in the Esophagus
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 33
- Registration Number
- NCT02879721
- Locations
- 🇸🇪
Dept. of Gastrosurgical Research and Education, Inst. Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 465
- Registration Number
- NCT02874794
- Locations
- 🇺🇸
Novartis Investigative Site, Manitowoc, Wisconsin, United States
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT02768298
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 393
- Registration Number
- NCT02678312
- Locations
- 🇹🇷
Novartis Investigative Site, Konak, Turkey
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 887
- Registration Number
- NCT02554890
- Locations
- 🇺🇸
Novartis Investigative Site, Wausau, Wisconsin, United States
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT02468232
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- InCor Heart Institute
- Target Recruit Count
- 76
- Registration Number
- NCT02432885
Relative Bioavailability Study With Enalapril in Healthy Volunteers
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Ethicare GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT02252692
- Locations
- 🇧🇪
Center for Clinical Pharmacology, UZ Leuven, Leuven, Belgium
Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 374
- Registration Number
- NCT02177461
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.